ACM
AMPH icon

Anfield Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Anfield Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,027
Closed -$28.8K – 71
2022
Q4 		$28.8K Buy
1,027
+413
+67% +$12K 0.01% 78
2022
Q3 		$17K Buy
614
+21
+4% +$686 0.01% 85
2022
Q2 		$21K Buy
593
+84
+17% +$3K 0.01% 87
2022
Q1 		$18K Buy
+509
New +$14.4K 0.01% 92

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Anfield Capital Management's AMPH Position: Q1 2023 in Review

Anfield Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2023, closing a stake of 1,027 shares — an estimated $28.8K sold.

Anfield Capital Management first reported a position in AMPH in Q1 2022 and held it in 4 quarters. The position peaked at $28.8K in Q4 2022. 218 funds tracked by Wall St. Rank hold AMPH as of Q1 2023.

  • Anfield Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Anfield Capital Management sold 1,027 Amphastar Pharmaceuticals shares in Q1 2023, an estimated $28.8K.
  • Anfield Capital Management first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Anfield Capital Management's Amphastar Pharmaceuticals position peaked at $28.8K in Q4 2022.
  • 218 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.